BackscPharmaceuticals Overview

scPharmaceuticals Total Revenue

Latest total revenue for SCPH: $50M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$16.04M
↑ 99.17% YoY

As of Jun 2025

Annual Revenue (TTM)

$49.97M
↑ 107.79% YoY

Trailing 12 months ending Jun 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

scPharmaceuticals (SCPH) FAQ

scPharmaceuticals (SCPH) currently reports a total revenue of $50M as of June 2025. That compares with $24M in the prior-year period — up 107.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore scPharmaceuticals's total revenue history and peer comparisons.

scPharmaceuticals's total revenue increased from $24M to $50M — a 107.8% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

scPharmaceuticals's total revenue of $50M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

scPharmaceuticals reported $50M in total revenue as of June 2025. That compares with $24M in the prior-year period — up 107.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $50M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for scPharmaceuticals, and consider following SCPH for alerts when major investors trade the stock.